Target intelligence / Profile preview

DNA topoisomerase 1-DNA cleavage complex (TOP1cc)

Target
TOP1cc
Molecular classification
Enzyme, Type IB topoisomerase
01

Overview

DNA topoisomerase 1 (TOP1) is a vital nuclear enzyme that regulates DNA topology by creating transient single-strand breaks to relieve torsional strain during replication and transcription (UniProt P11387). The Topoisomerase I – DNA cleavage complex (TOP1cc) is the specific catalytic intermediate where the enzyme is covalently linked to the 3' end of the DNA (Pommier, Nat Rev Cancer 2006). This complex is the primary pharmacological target for camptothecin derivatives and indenoisoquinolines, which act as interfacial inhibitors by binding at the DNA-enzyme interface (Thomas et al., Chem Rev 2004). By stabilizing the TOP1cc, these drugs prevent the religation of the DNA strand, leading to the formation of lethal double-strand breaks when the complex is encountered by replication forks (Murai et al., Cancer Res 2012). This mechanism is highly effective in treating various malignancies, including colorectal and small-cell lung cancers, although its clinical utility is often limited by toxicities such as severe myelosuppression and gastrointestinal distress (StatPearls, Irinotecan). Cellular resistance can also arise through the upregulation of repair enzymes like Tyrosyl-DNA phosphodiesterase 1 (TDP1), which can excise the trapped TOP1 from the DNA (Pommier, Nat Rev Cancer 2006).

Other names
TOP1-DNA covalent complexTopoisomerase I-DNA complexTOP1 cleavage complexDNA topoisomerase 1 (TOP1)
02

Mechanism of action

Interfacial inhibition that stabilizes the transient covalent TOP1-DNA cleavage complex, preventing DNA religation and causing replication fork collapse into lethal double-strand breaks.

03

Biological functions

DNA replicationTranscriptionDNA supercoiling relaxationChromatin remodelingDNA recombination
04

Disease associations

Cancer
05

Safety considerations

MyelosuppressionNeutropeniaSevere gastrointestinal toxicity (diarrhea)Cholinergic syndrome (associated with irinotecan)Acquired drug resistance via TDP1 upregulation
06

Interacting drugs

Camptothecin

7 more in the full profile.

07

Biomarkers

Schlafen 11 (SLFN11) expressionTyrosyl-DNA phosphodiesterase 1 (TDP1) activityTOP1 protein expression levelsXRCC1 expression

Beyond the preview

Go deeper on DNA topoisomerase 1-DNA cleavage complex (TOP1cc).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNA topoisomerase 1-DNA cleavage complex (TOP1cc).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call